Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.38 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BHMT | Q93088 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2775165 | 1.00 | TDP1 (0.46) | TDP1SMN1; SMN2SLC22A6CYP1A2TP53 | |
| SCHEMBL29193105 | 0.84 | TDP1 (0.37) | TDP1SMN1; SMN2SLC22A6CYP1A2TP53 | |
| SCHEMBL304303 | 0.82 | SLC22A6 (0.50) | TDP1SMN1; SMN2SLC22A6CYP1A2CACNA2D1 | |
| SCHEMBL5077944 | 0.82 | SLC22A6 (0.50) | TDP1SMN1; SMN2SLC22A6CYP1A2CACNA2D1 | |
| SCHEMBL8623416 | 0.82 | TDP1 (0.32) | TDP1SMN1; SMN2 | |
| SCHEMBL14632201 | 0.81 | SLC22A6 (0.39) | TDP1SMN1; SMN2SLC22A6CYP1A2CACNA2D1 | |
| SCHEMBL9857573 | 0.79 | RNPEP (0.36) | TDP1CYP1A2TP53 | |
| SCHEMBL16453428 | 0.78 | TDP1 (0.46) | TDP1SMN1; SMN2SLC22A6CYP1A2TP53 | |
| SCHEMBL17679177 | 0.78 | TDP1 (0.46) | TDP1SMN1; SMN2SLC22A6CYP1A2TP53 | |
| SCHEMBL148545 | 0.78 | TDP1 (0.46) | TDP1SMN1; SMN2SLC22A6CYP1A2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286979-A1 | SALT OF DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-09-14 | — | — | US | disclosed |
| CN-104487430-B | For the method manufacturing hydroxylated cyclopenta pyrimidine compound | 阵列生物制药公司 | 2016-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286979-A1 | SALT OF DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | FH, GRHPR, SDHB | TDP1 1680/4885SMN1; SMN2 4120/4885SLC22A6 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.